Ifp Advisors, Inc Incyte Corp Transaction History

Ifp Advisors, Inc

$3.07 Billion
Q1 2025

A detailed history of Ifp Advisors, Inc transactions in Incyte Corp stock. As of the latest transaction made, Ifp Advisors, Inc holds 2,374 shares of INCY stock, worth $154,143. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,374

Previous 2,532 6.24%

Holding current value

$154,143

Previous $174,000 17.82%

% of portfolio

0.0%

Previous 0.01%

38 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 05, 2025	SELL	$60.0 - $75.26 $9,480 - $11,891	-158 Reduced 6.24%	2,374 $143,000
Q4 2024 Feb 04, 2025	SELL	$65.08 - $83.38 $24,209 - $31,017	-372 Reduced 12.81%	2,532 $174,000
Q3 2024 Feb 04, 2025	BUY	$57.33 - $68.61 $24,307 - $29,090	424 Added 17.1%	2,904 $191,000
Q2 2024 Jul 30, 2024	BUY	$51.18 - $63.75 $1,637 - $2,040	32 Added 1.31%	2,480 $150,000
Q1 2024 Jul 30, 2024	BUY	$56.55 - $66.59 $2,148 - $2,530	38 Added 1.58%	2,448 $139,000
Q4 2023 Jan 09, 2024	BUY	$52.16 - $64.19 $18,725 - $23,044	359 Added 17.5%	2,410 $151,000
Q3 2023 Oct 12, 2023	BUY	$57.77 - $65.93 $346 - $395	6 Added 0.29%	2,051 $118,000
Q2 2023 Aug 04, 2023	SELL	$60.95 - $75.51 $22,063 - $27,334	-362 Reduced 15.04%	2,045 $127,000
Q1 2023 Apr 18, 2023	SELL	$70.23 - $86.01 $1.07 Million - $1.31 Million	-15,202 Reduced 86.33%	2,407 $173,000
Q4 2022 Feb 07, 2023	BUY	$67.18 - $84.11 $19,549 - $24,476	291 Added 1.68%	17,609 $1.2 Million
Q3 2022 Nov 08, 2022	BUY	$66.18 - $82.86 $40,700 - $50,958	615 Added 3.68%	17,318 $1.18 Million
Q2 2022 Sep 06, 2022	BUY	$66.18 - $83.18 $1.11 Million - $1.39 Million	16,703 New	16,703 $1.14 Million
Q2 2022 Aug 12, 2022	SELL	$66.18 - $83.18 $1.11 Million - $1.39 Million	-16,703 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$66.02 - $79.71 $1.01 Million - $1.22 Million	15,365 Added 1148.36%	16,703 $0
Q1 2022 Aug 08, 2022	BUY	$66.02 - $79.71 $60,078 - $72,536	910 Added 212.62%	1,338 $0
Q4 2021 Jan 12, 2022	BUY	$63.34 - $74.11 $3,357 - $3,927	53 Added 14.13%	428 $33,000
Q3 2021 Oct 06, 2021	BUY	$68.67 - $84.02 $3,502 - $4,285	51 Added 15.74%	375 $27,000
Q2 2021 Jul 13, 2021	BUY	$79.87 - $87.53 $23,162 - $25,383	290 Added 852.94%	324 $27,000
Q1 2021 Apr 30, 2021	SELL	$76.02 - $100.5 $3,040 - $4,020	-40 Reduced 54.05%	34 $3,000
Q4 2020 Jan 25, 2021	BUY	$80.74 - $97.7 $322 - $390	4 Added 5.71%	74 $6,000
Q3 2020 Oct 29, 2020	SELL	$85.07 - $109.69 $170 - $219	-2 Reduced 2.78%	70 $6,000
Q2 2020 Aug 05, 2020	BUY	$74.18 - $108.93 $1,186 - $1,742	16 Added 28.57%	72 $7,000
Q1 2020 May 12, 2020	BUY	$63.18 - $85.97 $2,021 - $2,751	32 Added 133.33%	56 $5,000
Q4 2019 Jan 17, 2020	SELL	$73.04 - $95.72 $1,606 - $2,105	-22 Reduced 47.83%	24 $2,000
Q3 2019 Nov 07, 2019	BUY	$72.82 - $86.52 $2,548 - $3,028	35 Added 318.18%	46 $4,000
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $14,745 - $20,455	-232 Reduced 95.47%	11 $1,000
Q4 2018 Jan 23, 2019	SELL	$58.5 - $69.94 $26,734 - $31,962	-457 Reduced 65.29%	243 $0
Q3 2018 Oct 25, 2018	BUY	$61.75 - $74.23 $1,111 - $1,336	18 Added 2.64%	700 $0
Q2 2018 Aug 07, 2018	SELL	$60.85 - $83.98 $669 - $923	-11 Reduced 1.59%	682 $0
Q1 2018 Jun 03, 2019	BUY	$83.06 - $100.98 $1,495 - $1,817	18 Added 2.67%	693 $66,000
Q1 2018 May 09, 2018	SELL	$83.06 - $100.98 $1,495 - $1,817	-18 Reduced 2.6%	675 $0
Q4 2017 Jan 24, 2018	SELL	$93.56 - $116.6 $26,477 - $32,997	-283 Reduced 29.0%	693 $0
Q3 2017 Oct 30, 2017	SELL	$109.15 - $138.27 $18,555 - $23,505	-170 Reduced 14.83%	976 $114,000
Q2 2017 Jun 03, 2019	BUY	N/A	103 Added 9.88%	1,146 $144,000
Q1 2017 Jun 03, 2019	BUY	N/A	66 Added 6.76%	1,043 $139,000
Q4 2016 Jun 03, 2019	BUY	N/A	323 Added 49.39%	977 $98,000
Q2 2016 Jun 03, 2019	BUY	N/A	643 Added 5845.45%	654 $52,000
Q1 2016 Jun 03, 2019	BUY	N/A	11	11 $1,000

Others Institutions Holding INCY

# of Institutions

695

Shares Held

194M

Call Options Held

564K

Put Options Held

331K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $14.4B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account